New hope for tough lymphoma: experimental cell therapy enters human trials
NCT ID NCT07476066
First seen Mar 19, 2026 · Last updated May 22, 2026 · Updated 12 times
Summary
This study tests an experimental treatment called SYS6055 in adults with aggressive B-cell lymphoma that has returned or not responded to standard therapy. The treatment uses specially modified immune cells (CAR-T cells) to target and attack cancer cells. The main goals are to check safety and find the best dose, while also seeing if it helps shrink tumors or extend life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.